LyGenesis is a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, type 1 diabetes, end stage renal disease, and aging.
LyGenesis’ technology enables one donor organ to treat dozens of patients, instead of one donor organ treating one patient.
LyGenesis was founded in 2017. The company is headquartered in Pittsburgh, Pennsylvania.
LyGenesis's regenerative cell therapies have the potential to transform the lives of patients who are either medically ineligible for an organ transplant or are awaiting an organ to become available.
LyGenesis's lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis's drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease).
LyGenesis is backed by Prime Movers Lab, Juvenescence, Longevity Vision Fund, and others. The company raised $19M in a Series A-2 round on Oct 24, 2023. This brings LyGenesis' total funding to $26M to date.